Nemaura Medical Inc. (NASDAQ: NMRD) Offers Sought-After Solutions in Areas of Unmet Medical Need

Rhea-AI Summary

Nemaura Medical Inc. (NASDAQ: NMRD) was featured in an editorial by NetworkNewsWire, highlighting the role of technology in addressing major healthcare challenges. The global healthcare market, valued at $8.45 trillion in 2018, is under pressure to improve efficiency and outcomes. Nemaura focuses on diabetes and obesity, offering noninvasive diagnostic devices like sugarBEAT, a CE-mark-approved glucose monitor, and proBEAT, an AI-driven subscription service. The company has submitted a PMA for sugarBEAT to the U.S. FDA, aiming to enhance diabetes management.

Positive

• Nemaura's sugarBEAT is a CE-mark-approved Class IIb medical device for glucose monitoring.
• proBEAT combines glucose data with AI and is launched as a general wellness product.

Negative

• None.

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Nemaura Medical Inc. (NASDAQ: NMRD) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, “Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle Diabetes, Obesity,” please visit: https://nnw.fm/aKQpJ

Exorbitant costs underscored by byzantine processes plague today’s healthcare systems, creating an $8.45 trillion global healthcare market in 2018, which represents about 10% of GDP in developed countries. Safe to say, the industry is looking for solutions, particularly more efficient ones that improve health outcomes and lower direct and indirect costs.

The answer is found in technology, with healthtech (healthcare technology) and medtech (medical technology) buzzwords speaking to leveraging next-generation innovation in a bid to flatten the healthcare spending curve. New applications are being launched daily, and uptake is accelerating, fanned by the COVID-19 pandemic that bolstered adoption of self-diagnostic and remote solutions that have been embraced by health insurers and individuals alike. Some companies, such as Nemaura Medical Inc. (NASDAQ: NMRD), are specializing in certain areas of unmet medical need, such as diabetes and obesity.

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE-mark-approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (premarket approval application) for sugarBEAT to the U.S. FDA. proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital health-care subscription service and has been launched in the United States. as a general wellness product as part of its BEAT(R) diabetes program.

For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is Nemaura Medical Inc.'s focus regarding healthcare solutions?

Nemaura Medical Inc. specializes in noninvasive diagnostic devices for diabetes and obesity.

What products does Nemaura offer for diabetes management?

Nemaura offers sugarBEAT, a glucose monitoring device, and proBEAT, an AI-supported wellness product.

When did Nemaura Medical announce their editorial feature?

Nemaura Medical announced its editorial feature on September 22, 2021.

What regulatory application has Nemaura submitted for sugarBEAT?

Nemaura has submitted a premarket approval application (PMA) for sugarBEAT to the U.S. FDA.

How large is the global healthcare market mentioned in the press release?

The global healthcare market was valued at $8.45 trillion in 2018.